Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neurotech International ( (AU:NTI) ) has shared an announcement.
Neurotech International Limited has received a $4.73 million R&D tax incentive refund from the Australian Government for the financial year ending June 2025. The company plans to use these funds to further develop its clinical pipeline for paediatric neurological disorders and support its working capital, potentially enhancing its operational capabilities and market position in the biopharmaceutical industry.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for paediatric neurological disorders. The company is known for its broad-spectrum oral cannabinoid drug therapy, NTI164, and has conducted various clinical trials in disorders such as Autism Spectrum Disorder, PANDAS/PANS, and Rett Syndrome. Neurotech is also advancing clinical trials for spastic cerebral palsy.
Average Trading Volume: 1,497,478
Technical Sentiment Signal: Sell
Current Market Cap: A$17.84M
See more insights into NTI stock on TipRanks’ Stock Analysis page.